发明公开
EP1951296A2 CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA
有权
残余细胞DNA的低量的CELL ORIGINATING病毒疫苗
- 专利标题： CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA
- 专利标题（中）： 残余细胞DNA的低量的CELL ORIGINATING病毒疫苗
-
申请号： EP06831855.9申请日： 2006-11-01
-
公开(公告)号： EP1951296A2公开(公告)日： 2008-08-06
- 发明人: GREGERSEN, Jens-Peter , KOST, Holger
- 申请人： Novartis Vaccines and Diagnostics GmbH & Co. KG
- 申请人地址： Emil-von-Behring-Strasse 76 35041 Marburg DE
- 专利权人： Novartis Vaccines and Diagnostics GmbH & Co. KG
- 当前专利权人： Novartis Vaccines and Diagnostics GmbH & Co. KG
- 当前专利权人地址： Emil-von-Behring-Strasse 76 35041 Marburg DE
- 代理机构： Marshall, Cameron John
- 优先权： US732786P 20051101
- 国际公布： WO2007052163 20070510
- 主分类号： A61K39/13
- IPC分类号： A61K39/13 ; A61K39/145
摘要：
The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as β-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
公开/授权文献
信息查询
